Navigation Links
Elekta To Showcase Innovations in Radiotherapy and Unveil New Product That Expands Cancer Treatment Availability
Date:9/6/2007

mposium.

Elekta also will hold a European Users' meeting September 7 at the Hotel Rey Juan Carlos I in Barcelona. Elekta Users will attend presentations on Elekta Treatment Solutions for management information systems, IGRT and VMAT.

*VMAT is a work in progress and currently not available for distribution.

About Elekta

Elekta is an international medical-technology Group, providing meaningful clinical solutions, comprehensive information systems and services for improved cancer care and management of brain disorders. All of Elekta's solutions employ non-invasive or minimally invasive techniques and are therefore clinically effective, gentle on the patient and cost-effective.

Clinical solutions include, among others, Leksell Gamma Knife(R) product line for non-invasive treatment of brain disorders, Elekta Axesse(TM) for Image guided Stereotactic treatments, and Elekta Synergy(R) for intensity modulated radiation therapy (IMRT) and image guided radiation therapy (IGRT). Following the acquisition of IMPAC Medical Systems Inc. in April 2005, the Elekta Group became the world's largest supplier of oncology software.

Elekta's systems and solutions are used at over 4,000 hospitals around the world to treat cancer and manage clinical operations as well as to diagnose and treat brain disorders, including tumors, vascular malformations and functional disorders.

With approximately 2,000 employees, Elekta's corporate headquarters is located in Stockholm, Sweden and the company is listed on the Nordic Exchange under the ticker EKTAb. For more information about Elekta, please visit http://www.elekta.com.


'/>"/>
SOURCE Elekta, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. BIO provides forum for Wisconsin to showcase strengths
2. EForum to showcase Southeast Wisconsin tech entrepreneurship
3. Life-sciences conference showcases capital ideas of Wisconsin
4. Modine showcases CO2 cooled Jeep
5. Johnson Controls To Showcase New Technologies for the Auto Industry
6. Conference to Showcase Regions Biotech Companies
7. Pilot fund brings capital to Eau Claire area innovations
8. Wisconsin state agencies commended for digital innovations
9. Oshkoshs Pierce Security Vehicle Ranked in top 100 Technological Innovations for 2003
10. Merge unveils next-generation imaging-informatics product
11. Merge unveils updated medical imaging software
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/15/2009)... Reportlinker.com announces that a new market research ... The Future of Orphan Diseases ... Analysis and Reimbursement ,, ... Summary ,, The author has released ... Diseases Therapeutics - Market Forecasts to 2015, ...
(Date:12/15/2009)... Minn., Dec. 15 The Mosaic Company (NYSE: ... fiscal year 2010 earnings results and financial tables on ... on the New York Stock Exchange. Results will ... ,, The Company will host a conference call with ... the results. The call will begin at 11:00 ...
(Date:12/15/2009)... PHILADELPHIA and LONDON, Dec. 15 ... Thomson Pharma ® has become the first ... trial protocol and outcome information. This highly anticipated ... Pharma customers this month. ,, ... trial intelligence from registries, publications, press releases, conferences, ...
(Date:12/14/2009)... -- Vermillion, Inc. (Pink Sheets: VRML), a ... Wallen, Ph.D. Chief Scientific Officer, Senior Vice ... will be joining its board of directors ... ,, "Bill brings more than 20 years ... biotechnology," said Gail Page, Vermillion Executive Chairperson. ...
Breaking Biology Technology:Reportlinker Adds The Future of Orphan Diseases Therapeutics - Market Forecasts to 2015, Pipeline Analysis and Reimbursement 2Reportlinker Adds The Future of Orphan Diseases Therapeutics - Market Forecasts to 2015, Pipeline Analysis and Reimbursement 3Reportlinker Adds The Future of Orphan Diseases Therapeutics - Market Forecasts to 2015, Pipeline Analysis and Reimbursement 4Reportlinker Adds The Future of Orphan Diseases Therapeutics - Market Forecasts to 2015, Pipeline Analysis and Reimbursement 5Reportlinker Adds The Future of Orphan Diseases Therapeutics - Market Forecasts to 2015, Pipeline Analysis and Reimbursement 6Reportlinker Adds The Future of Orphan Diseases Therapeutics - Market Forecasts to 2015, Pipeline Analysis and Reimbursement 7Reportlinker Adds The Future of Orphan Diseases Therapeutics - Market Forecasts to 2015, Pipeline Analysis and Reimbursement 8Reportlinker Adds The Future of Orphan Diseases Therapeutics - Market Forecasts to 2015, Pipeline Analysis and Reimbursement 9Reportlinker Adds The Future of Orphan Diseases Therapeutics - Market Forecasts to 2015, Pipeline Analysis and Reimbursement 10Reportlinker Adds The Future of Orphan Diseases Therapeutics - Market Forecasts to 2015, Pipeline Analysis and Reimbursement 11Reportlinker Adds The Future of Orphan Diseases Therapeutics - Market Forecasts to 2015, Pipeline Analysis and Reimbursement 12Reportlinker Adds The Future of Orphan Diseases Therapeutics - Market Forecasts to 2015, Pipeline Analysis and Reimbursement 13Reportlinker Adds The Future of Orphan Diseases Therapeutics - Market Forecasts to 2015, Pipeline Analysis and Reimbursement 14Reportlinker Adds The Future of Orphan Diseases Therapeutics - Market Forecasts to 2015, Pipeline Analysis and Reimbursement 15Reportlinker Adds The Future of Orphan Diseases Therapeutics - Market Forecasts to 2015, Pipeline Analysis and Reimbursement 16Reportlinker Adds The Future of Orphan Diseases Therapeutics - Market Forecasts to 2015, Pipeline Analysis and Reimbursement 17Reportlinker Adds The Future of Orphan Diseases Therapeutics - Market Forecasts to 2015, Pipeline Analysis and Reimbursement 18Mosaic Announces Second Quarter Fiscal Year 2010 Earnings Release and Conference Call 2Thomson Reuters is First to Offer Fully Integrated Pipeline and Clinical Trials 2Vermillion Announces Appointment of William C. Wallen, Ph.D. to Board of Directors 2Vermillion Announces Appointment of William C. Wallen, Ph.D. to Board of Directors 3Vermillion Announces Appointment of William C. Wallen, Ph.D. to Board of Directors 4
... Orchid Cellmark Inc.,(Nasdaq: ORCH ), a leading ... its third quarter 2007 financial results on,Thursday, November ... is hosting a,conference call and webcast to discuss ... day. Management will discuss financial results for the ...
... Telik, Inc.,(Nasdaq: TELK ) announced that the ... partial hold on TELCYTA(R) (canfosfamide HCl, TLK286),clinical trials. ... data by,the agency and permits the resumption of ... Alto, CA is a biopharmaceutical company focused on,discovering, ...
... relying on external technologies sourced from start-ups, research ... interact to bring science-driven innovation to market" This ... at the third annual Lux Executive Summit: Connecting ... 15-16, 2007 at the Charles Hotel in Cambridge, ...
Other Biology Technology:Orchid Cellmark to Announce Third Quarter 2007 Financial Results on November 1, 2007 2FDA Removes Partial Hold on TELCYTA Clinical Development 2Lux Executive Summit announces 2007 speakers 2
(Date:12/16/2009)... Tom Bowman, an expert in communicating scientific issues to ... developed a series of graphics that translate key figures ... report for public audiences. These new graphics provide non-experts ... make informed decisions about climate change risks and opportunities. ... to clearly and accurately communicate findings in the IPCC ...
(Date:12/16/2009)... 1 iQor, a global provider of business ... InfoWorld 100 Awards Top 100 IT project ... was the first submission for iQor. ,, "We are ... companies," said Vikas Kapoor, president and CEO of iQor. ... allowing us to work faster, smarter and with the ...
(Date:12/16/2009)... REDWOOD CITY, Calif., Dec. 2 ... and authentication solutions, today announced an agreement ... of its DigitalPersona biometric fingerprint technology on ... U.are.U® 4500HD offering allows point-of-sale applications to ... that specific transactions can be linked to ...
Breaking Biology News(10 mins):Bowman creates graphic translation of climate change data 2iQor Named to InfoWorld 100 List of Top IT Projects of 2009 2DigitalPersona Fingerprint Sensor Technology Ships on IBM SurePOS 500 Retail Systems 2Injection Reverses Heart Attack Damage 4771 1Injection Reverses Heart Attack Damage 4771 2Injection Reverses Heart Attack Damage 4771 3Injection May Heal Damaged Heart 52560 1Injection May Heal Damaged Heart 52560 2International Health Leaders to Share Innovations in Patient Centered Care at 2009 Planetree Annual Conference 52555 1International Health Leaders to Share Innovations in Patient Centered Care at 2009 Planetree Annual Conference 52555 2International Health Leaders to Share Innovations in Patient Centered Care at 2009 Planetree Annual Conference 52555 3
... and gas prices along with the global challenge of ... search for alternative energy sources. A national panel of ... National Meeting in New Orleans to present a comprehensive ... of several significant renewable energy sources. , The ...
... -- Research by two Queens scientists has resulted in an ... such as chemical weapons and pesticides. , Recently completed testing ... method to be greater than 99 per cent effective when ... , When tested in solution, full destruction of all three ...
... research team from the Department of Genetics, Physical Anthropology ... Technology at the Leioa campus of the University of ... de la Ra, has reconstructed the history of the ... using DNA extracted from skeleton remains. , Knowing the ...
Other Biology News:Symposium on energy research highlights future challenges, opportunities 2Queen's develops safe 'green' decontamination method 2Ancient DNA: reconstruction of the biological history of Aldaieta necropolis 2Ancient DNA: reconstruction of the biological history of Aldaieta necropolis 3
One-step, microplate or cuvet, colorimetric, detection range 0.01 g/dL to 5 g/dL. Procedure: 5 min....
MOUSE ANTI PROTEIN KINASE C BETA 2 Immunogen: Protein kinase C beta 2...
SHEEP ANTI DEHYDROEPIANDROSTERONE...
This issue concentrated on the purification of proteins for specific purposes (i.e. large-scale purification, purification for therapeutic use, etc.)...
Biology Products: